ALEXANDRIA, Va., July 16 -- United States Patent no. 12,357,690, issued on July 15, was assigned to Cellaster Inc. (Incheon, South Korea).
"Epitope of EPB41L5, and monoclonal antibody" was invented by Kyung Chul Choi (Seoul, South Korea), Ho Geun Yoon (Goyang-si, South Korea), Jae Ho Cheong (Seoul, South Korea) and Mi Hyeon Jeong (Jeonju-si, South Korea).
According to the abstract* released by the U.S. Patent & Trademark Office: "In the present disclosure, the effect of the TGFBeta/Smad3/EPB41L5 molecular mechanism on cancer cells has been identified, and it has been found that high expression of EPB41L5 is correlated with poor overall survival of cancer patients, indicating that EPB41L5 is a potential prognostic marker of cancer. Thus, t...